Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
68 hedge funds and large institutions have $87.2M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 12 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 69 → 68 (-1)
39% less capital invested
Capital invested by funds: $144M → $87.2M (-$56.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.63M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.09M |
| 3 |
BlackRock
New York
|
+$800K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$634K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.59M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.54M |
| 3 |
SCM
Sio Capital Management
New York
|
-$969K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$818K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$687K |
PRDS Hedge Fund Activity: Q3 2022 in Review
68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2022, worth a combined $87.2M — down 39% from $144M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRDS and 11 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 23 added.
The largest buyer was Goldman Sachs, adding an estimated $4.63M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.59M.
- 68 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2022, down from 69 in Q2 2022.
- Funds reported $87.2M of Pardes Biosciences, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
- 11 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -1 holder.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2022 was Goldman Sachs, an estimated $4.63M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2022 was T. Rowe Price Associates, an estimated $1.59M sold.
Based on aggregated 13F filings for Q3 2022.